← back to search

Fei Liu

Shenzhen Sixth People's Hospital · CN
Area of research
Cancer Research · Nephrology
Research interest
Research interests include MicroRNA in disease regulation, Renal Diseases and Glomerulopathies, Hepatocellular Carcinoma Treatment and Prognosis, and Epigenetics and DNA Methylation.
h-index
69
citations
23,786
works
1,114
NIH funding
primary concept
email

Recent publications

Molecular mechanism of macrophage polarization regulating the cell senescence of nucleus pulposus during intervertebral disc degeneration
International Immunopharmacology 2025cited by 16position: middledoi
Gut microbiome dysbiosis accelerates osteoarthritis progression by inducing IFP-SM inflammation in “double-hit” mice
Arthritis Research & Therapy 2025cited by 7position: middledoi
Consistency and Heterogeneity of Microsatellite Instability (MSI) Status in Paired Biopsy and Surgical Specimens of Colorectal Cancer: A Necessity for MSI Reassessment After Treatment?
JCO Precision Oncology 2025cited by 1position: middledoi
High cellular plasticity state of medulloblastoma local recurrence and distant dissemination
Cell Reports Medicine 2025cited by 0position: middledoi
Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer
Cell Reports Medicine 2025cited by 0position: middledoi
Molecular mechanism of mechanical pressure induced changes in the microenvironment of intervertebral disc degeneration
Inflammation Research 2024cited by 30position: firstdoi
Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers
Cell Reports Medicine 2024cited by 23position: middledoi
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement
Molecular Therapy 2024cited by 23position: firstdoi
A new strategy to generate nanobodies for the coumaphos based on the synthesized nanobody libraries
Food Chemistry 2024cited by 13position: middledoi
From gut to kidney: microbiota modulates stone risk through inflammation–a mediated Mendelian randomization study
Mammalian Genome 2024cited by 9position: lastdoi
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
The Lancet Regional Health - Western Pacific 2024cited by 6position: middledoi
Study on pharmacokinetics and tissue distribution of deoxypodophyllotoxin and its metabolites in tumour-bearing mice
Xenobiotica 2024cited by 2position: firstdoi
Disparity in risk factors of ischemic stroke in four coastal-area hospitals in China
Heliyon 2024cited by 1position: middledoi
Exploring Shape and Colors from Existing Silk Scarf by Integrating Chinese Dunhuang Mural Elements to Contemporary Perception from Historical Evolution and Cultural Perspective in China
Herança 2024cited by 1position: contributordoi
Molecular mechanism of the influence of related genes expression in synoviumtissue around shoulder joint of secondary frozen shoulder model rats onangiogenesis
Cellular and Molecular Biology 2024cited by 0position: middledoi
The Strategic Path and Policy Consideration of Trade of Cultural Products Among WTO Member Countries: Taking the Circulation of Cultural Products Derived from Dunhuang Murals as an Example
China and WTO Review 2024cited by 0position: contributordoi
Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy
Free Radical Biology and Medicine 2023cited by 52position: middledoi
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing Tool
Advanced Science 2023cited by 34position: middledoi
Radiomics feature analysis and model research for predicting histopathological subtypes of non‐small cell lung cancer on CT images: A multi‐dataset study
Medical Physics 2023cited by 30position: middledoi
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
BMC Medicine 2023cited by 21position: middledoi
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis
Photodiagnosis and Photodynamic Therapy 2023cited by 14position: middledoi
Umbilical artery ultrasound haemodynamics combined with serum adiponectin levels can aid in predicting adverse pregnancy outcomes in patients with severe pre-eclampsia
Journal of Obstetrics and Gynaecology 2023cited by 8position: middledoi
Four novel sleep-promoting peptides screened and identified from bovine casein hydrolysates using a patch-clamp model <i>in vitro</i> and <i>Caenorhabditis elegans in vivo</i>
Food & Function 2023cited by 7position: middledoi
Prevalence and risk factors for minimal hepatic encephalopathy in cirrhotic patients with different etiologies
Portal hypertension & cirrhosis 2023cited by 3position: middledoi
IDDF2023-ABS-0075 A prospective, multicenter study of minimal hepatic encephalopathy prevalence and relationship with quality of life in patients with cirrhosis in china
2023cited by 0position: middledoi
Additional file 4 of Comparative genomics of smut fungi suggest the ability of meiosis and mating in asexual species of the genus Pseudozyma (Ustilaginales)
Figshare 2023cited by 0position: middledoi
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
The Lancet Respiratory Medicine 2022cited by 224position: middledoi
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
Journal of Thoracic Oncology 2022cited by 76position: middledoi
Exosome-Encapsulated microRNA-140-5p Alleviates Neuronal Injury Following Subarachnoid Hemorrhage by Regulating IGFBP5-Mediated PI3K/AKT Signaling Pathway
Molecular Neurobiology 2022cited by 46position: middledoi
HIF-1α Causes LCMT1/PP2A Deficiency and Mediates Tau Hyperphosphorylation and Cognitive Dysfunction during Chronic Hypoxia
International Journal of Molecular Sciences 2022cited by 37position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Meixiang Sang · Shanghai University of Electric Power7 papers (2015–2020)Jianyin Miao · South China Agricultural University5 papers (2017–2023)Ying Cheng · Changzhi University5 papers (2022–2024)Aimin Zang · Chinese Academy of Medical Sciences & Peking Union Medical College5 papers (2022–2024)Yong Cao · South China Agricultural University5 papers (2017–2023)Shucai Zhang · Northeastern University5 papers (2022–2024)Hui Zhao · Anhui Medical University5 papers (2022–2024)Jiwei Liu · Harbin Medical University5 papers (2022–2024)Shuyang Zhu · Xuzhou Medical College5 papers (2022–2024)Yunpeng Liu · Shenyang Institute of Automation5 papers (2022–2024)Jian Feng · Jinzhou Medical University4 papers (2022–2024)Shengwei Sun · South China Agricultural University4 papers (2017–2021)Gongyan Chen · Harbin Medical University4 papers (2022–2024)Lin Wu · Central South University4 papers (2022–2024)Guo Liu · Changsha Medical University4 papers (2017–2023)Yuping Li · Guangxi Medical University4 papers (2022–2024)Lina Gu · Hebei Medical University4 papers (2015–2018)Lejie Cao · University of Science and Technology of China4 papers (2022–2024)Nong Yang · The First Affiliated Hospital, Sun Yat-sen University3 papers (2022–2024) · 3 papers (2022–2022)